African children should widely get the only approved vaccine against malaria, possibly paving the way for further progress against a disease that claims the lives of hundreds of thousands of people each year.
The WHO recommended vaccine is RTS,S produced by United Kingdom based pharmaceutical GlaxoSmithKline. The vaccine’s efficacy in preventing severe instances of malaria in children is only around 30%, yet it is the only one that has been authorized.
“This is a vaccine developed in Africa by African scientists and we’re very proud,” said WHO director-general Tedros Adhanom Ghebreyesus, quoted by Reuters. “This vaccine is a gift to the world but its value will be felt most in Africa.”
So far in 2019, the WHO has organized a large-scale pilot study to give 2.3 million doses of Mosquirix to babies in Ghana, Kenya, and Malawi. The illness mostly affects children under the age of five.
In Africa, malaria is a much greater killer than Covid-19. According to WHO estimates, it killed 386,000 Africans in 2019, compared to the 212,000 fatalities from Covid-19 in the previous 18 months.
According to the WHO, 94% of malaria infections and fatalities occur on the continent of Africa, home to a population of 1.3 billion. The illness is caused by parasites that are spread to humans via the bites of infected mosquitoes.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.